Stockscreener 앱 받기
6.27
0.64%
0.04
시간 외 거래:
6.27
전일 마감가:
$6.23
열려 있는:
$6.2
하루 거래량:
2.65M
Relative Volume:
0.53
시가총액:
$1.63B
수익:
$6.22B
순이익/손실:
$187.00M
주가수익비율:
8.7497
EPS:
0.7166
순현금흐름:
$508.00M
1주 성능:
-0.95%
1개월 성능:
-16.62%
6개월 성능:
-40.00%
1년 성능:
-60.29%
1일 변동 폭
$6.1802
$6.31
1주일 범위
$6.155
$6.53
52주 변동 폭
$6.155
$15.85
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.27 | 1.62B | 6.22B | 187.00M | 508.00M | 0.7166 |
|
LLY
Lilly Eli Co
|
917.50 | 819.81B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.60 | 571.52B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
206.23 | 368.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
188.93 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
148.19 | 285.86B | 54.72B | 14.02B | 15.32B | 7.1855 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-10-27 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Organon & Co stock hits 52-week low at 6.17 USD By Investing.com - Investing.com South Africa
Organon & Co stock hits 52-week low at 6.17 USD - Investing.com Australia
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance Singapore
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility (IJR:NYSEARCA) - Seeking Alpha
Organon & Co. (NYSE:OGN) Hits New 12-Month LowHere's Why - MarketBeat
Organon rises after update on independent review - MSN
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Investors heavily search Organon & Co. (OGN): Here is what you need to know - MSN
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo! Finance Canada
Aug Wrap: Can Organon Co expand into new marketsWeekly Trade Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
Organon & Co. Experiences Evaluation Revision Amidst Market Challenges and Performance Divergence - Markets Mojo
Gotham Asset Management LLC Buys 1,007,691 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Organon & Co. (OGN) Dividend Yield 2026, Date & History $OGN - MarketBeat
OGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com Nigeria
Organon trades in red for seven straight sessions - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Shareholders to Reach Out - ACCESS Newswire
(OGN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives - Sahm
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN
Royce & Associates LP Trims Position in Organon & Co. $OGN - MarketBeat
Organon climbs 6% after audit clears company of wrongdoing - MSN
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Organon & Co. Hits Day Low of $7.50 Amid Price Pressure - Markets Mojo
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Organon (OGN) HR chief gets stock awards, withholds shares for taxes - Stock Titan
Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February - MarketBeat
Organon (OGN) CFO granted shares, withholds stock to pay taxes - Stock Titan
Organon (OGN) executive reports PSU share awards and tax withholding - Stock Titan
Organon (OGN) CIO logs stock awards and tax withholding share disposals - Stock Titan
Organon (OGN) GC Weaver gets stock awards, shares withheld for tax - Stock Titan
Organon (NYSE: OGN) interim CEO reports stock awards and tax share offsets - Stock Titan
Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity? - simplywall.st
Organon & Co. (OGN) Stock Analysis: Key Insights On Its 25.17% Potential Upside - DirectorsTalk Interviews
KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome - marketscreener.com
KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS - GlobeNewswire Inc.
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages - MarketBeat
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis - Bitget
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Organon (OGN) Pricing Reflect Its Value After Reported Sun Pharma Takeover Interest - Yahoo Finance
OGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Organon presents sleep improvement data for VTAMA cream in children By Investing.com - Investing.com Australia
Assessing Organon (OGN) Valuation After VTAMA Sleep Outcome Data From Phase 3 ADORING Trials - simplywall.st
Organon presents sleep improvement data for VTAMA cream in children - Investing.com
Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN - MarketBeat
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis - Business Wire
Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit - simplywall.st
Organon & Co. Confronts Mounting Global Pricing Pressure as Health Reforms Threaten Margin Stability and Nexplanon Growth - TipRanks
Organon & Co. (NYSE:OGN) Trading Down 6.3%Time to Sell? - MarketBeat
Organon & Co. (OGN) Stock Analysis: Navigating a Potential Upside Amidst a Challenging Landscape - DirectorsTalk Interviews
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
0.99%
자본화:
|
볼륨(24시간):